一分钟看懂
这是一项关于卵巢癌的I 期 / II 期研究，登记的药物或干预包括Rina-S；Carboplatin；Bevacizumab；Pembrolizumab；Erythromycin；Itraconazole，当前状态为招募中。登记地点显示中国北京、福建省、广东省、河南省等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Rina-S；Carboplatin；Bevacizumab；Pembrolizumab；Erythromycin；Itraconazole · I 期 / II 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出3项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Cancer hospital, Chinese Academy of Medical Sciences · 北京
- Fujian Cancer Hospital · 福建省
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University · 广东省
- Second Affiliated Hospital of Zhengzhou University · 河南省
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology · 湖北省
- Second Hospital of Shanxi Medical University · 山西省
- Shanxi Cancer Hospital · 山西省
- Liaoning Cancer Hospital & Institute · 沈阳
- Tianjin Cancer Hospital · 天津
- Chongqing University Cancer Hospital · 重庆
- Hunan Cancer Hospital - Phase 1 · 长沙
- Hunan Cancer Hospital - Thoracic Medicine Dept II · 长沙
- Jiangxi Maternal and Child Health Hospital · 南昌
- Jilin Cancer Hospital · 长春
- Obstetrics & Gynecology Hospital of Fudan University · 成都
- Fudan University Shanghai Cancer Center - Gynecologic Oncology · 上海
- Fudan University Shanghai Cancer Center- Phase 1 · 上海
- Shanghai East Hospital · 上海
- Sichuan Cancer Hospital · 上海
- Zhejiang Cancer Hospital · 杭州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- Part A and B:
- * Histologically or cytologically confirmed metastatic or unresectable solid malignancy including ovarian cancer (must have epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer), endometrial cancer, non-small cell lung cancer (Part A), EGFR-mutated NSCLC (Part B), breast cancer (hormone receptor positive, HER2-negative and triple-negative) (Part A), mesothelioma or cervical cancer (Part B).
- * Previously received therapies known to confer clinical benefit.
- * Measurable disease per RECIST v1.1 for all tumor types other than pleural mesothelioma which will use mRECIST v1.1 at baseline.
- Part C, E, and H:
- Participants must have histologically or cytologically confirmed metastatic or unresectable epithelial ovarian cancer as specified below.
- * High grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (excluding endometrioid, clear cell carcinomas, mucinous, low grade, and those with a sarcomatous or neuroendocrine element)
- * Participants must have received up to 3 prior lines of therapy. Participants may have had up to to 4 prior lines of therapy are allowed if MIRV is locally approved and was used as the last line of therapy. Participants must have progressed radiographically on or after their most recent line of therapy.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05579366；登记信息更新于 2026-10-07；本站同步于 2026-10-07，中国中心当前名额未经人工确认。